Treatment of Post-COVID-19 POTS by inhibiting FcRn: a phase 2 randomized, placebo controlled, double-blind, proof of concept study with efgartigimod

Back

ESC Professional Premium Access

Treatment of Post-COVID-19 POTS by inhibiting FcRn: a phase 2 randomized, placebo controlled, double-blind, proof of concept study with efgartigimod

Session: Long-term impact of COVID-19: direct and indirect consequences

Topic: Autoimmune/Chronic Inflammatory Disorders and Heart Disease

Speaker: Doctor J. van Middendorp (Gent, NL)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Joost van Middendorp

Gent (Netherlands (The))

0 follower

5 more presentations in this session

Substantial morbidity and mortality due to cardiovascular diseases in hospitalized vaccinated and un-vaccinated patients with COVID-19 from 16 countries: the WHF COVID-19 Long-term study

Speaker: Doctor K. Singh (Haryana, IN)

Vaccination status and long COVID symptoms among patients hospitalized with COVID-19: the WHF COVID-19 Long-term Study

Speaker: Professor D. Prabhakaran (Gurgaon, IN)

Effect of COVID-19 pandemic on the management of hypertension and the prevalence of lifestyle disease

Speaker: Doctor T. Isogaki (Hamamatsu, JP)

Effects of deferment of clinic visit on cardiovascular outcomes during COVID-19 outbreak: a prospective cohort study

Speaker: Assistant Professor G. Tan (Shatin, HK)

The effect of 2 years COVID-19 pandemic on myocardial infarction and stroke admissions: nationwide registry study, sex differences and mortality

Speaker: Assistant Professor P. Sedova (Brno, CZ)

Access the full session

Long-term impact of COVID-19: direct and indirect consequences

Speakers: Doctor J. van Middendorp, Doctor K. Singh, Professor D. Prabhakaran, Doctor T. Isogaki, Assistant Professor G. Tan...

Access

Video

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources